跳转至内容
Merck
CN

V900323

羟基脲

Vetec, reagent grade, ≥98%

别名:

羟基尿素

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

线性分子式:
NH2CONHOH
化学文摘社编号:
分子量:
76.05
EC Number:
204-821-7
UNSPSC Code:
12352200
PubChem Substance ID:
Beilstein/REAXYS Number:
1741548
MDL number:
Assay:
≥98%
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

reagent grade

product line

Vetec

assay

≥98%

storage temp.

2-8°C

SMILES string

NC(=O)NO

InChI

1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)

InChI key

VSNHCAURESNICA-UHFFFAOYSA-N

Gene Information

Biochem/physiol Actions

抗肿瘤剂。通过形成自由基硝基氧灭活核糖核苷还原酶,自由基硝基氧可结合到酶活性位点的酪氨酰自由基。这可阻断脱氧核苷酸的合成,从而抑制 DNA 合成,并且诱导细胞周期同步化或 S-期细胞死亡。

Legal Information

Vetec is a trademark of Merck KGaA, Darmstadt, Germany


Still not finding the right product?

Explore all of our products under 羟基脲


pictograms

Health hazard

signalword

Danger

hcodes

Hazard Classifications

Muta. 1B - Repr. 2

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Deepa Manwani et al.
Blood, 122(24), 3892-3898 (2013-09-21)
Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted
Winfred C Wang et al.
Pediatrics, 132(4), 677-683 (2013-09-04)
In the BABY HUG trial, young children with sickle cell anemia randomized to receive hydroxyurea had fewer episodes of pain, hospitalization, and transfusions. With anticipated broader use of hydroxyurea in this population, we sought to estimate medical costs of care
Guido Finazzi et al.
British journal of haematology, 161(5), 688-694 (2013-04-12)
Givinostat, a histone-deacetylase inhibitor (HDACi), inhibits proliferation of cells bearing the JAK2 V617F mutation and has shown significant activity with good tolerability in patients with chronic myeloproliferative neoplasms (MPN). In this multicentre, open-label, phase II study, 44 patients with polycythaemia



全球贸易项目编号

货号GTIN
V900323-100G04061833026205
V900323-250G04061833026212